OakChart

Cadrenal Therapeutics Inc

CVKDHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 2:25 PM ET

1.38-0.06 (-4.17%)
2026-11-11 20:26 CET
Market cap
5.14 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-11.54 USD m
Free cash flow, TTM
-10.16 USD m
EPS diluted, TTM
-4.90
P/E
-
Compare

Price

CVKD against its 20, 50 and 200-day averages
2050200beat
2.004.006.008.0010.8M21.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CVKDclose 1.3820-day 1.0650-day 1.08200-day 3.691.3852w low

89.4% under the 52-week high of 13.01 on 12 Nov 2025. 52-week low 0.82 on 12 Oct 2026. Last 15 sessions, 73.3% high to low

Profile

CVKD
52-week range, 5% of the way up
0.8213.01

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Employees5
IPOJan 20, 2023
Beta1.75
ATR, 14d0.14
Rel volume0.21
Short float7.16%
Insider own9.66%
Inst own11.68%

Snapshot

6 groups

Valuation

Index-
Market Cap4.93M
Enterprise Value2.54M
Income-11.54M
Sales0.00M
Book/sh1.32
Cash/sh0.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOJan 20, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.05
P/C2.06
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.67
Current Ratio3.67
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.90
EPS next Y-3.01
EPS next Q-0.91
EPS this Y41.82%
EPS next Y22.17%
EPS next 5Y34.69%
EPS past 3/5Y8.46% -
Sales past 3/5Y- -
EPS Y/Y TTM44.80%
Sales Y/Y TTM-
EPS Q/Q38.99%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.19.72% -

Ownership

Insider Own9.66%
Insider Trans-22.04%
Inst Own11.68%
Inst Trans17.45%
ROA-199.59%
ROE-275.16%
ROIC-282.13%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2029.95%
SMA5028.19%
SMA200-62.57%
Trades-

Technical

Shs Outstand3.57M
Shs Float3.22M
Short Float7.16%
Short Ratio0.48
Short Interest0.23M
52W High13.01 -89.39%
52W Low0.82 69.06%
Volatility17.86% 13.28%
ATR (14)0.14
RSI (14)64.95
Beta1.75
Rel Volume0.21
Avg Volume476.30K
Volume78,197

Performance

Perf Week30.19%
Perf Month38.42%
Perf Quarter-25.81%
Perf Half Y-74.01%
Perf YTD-79.65%
Perf Year-88.83%
Perf 3Y-78.20%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price14.00
Prev Close1.44
Price1.38
Change %-4.17%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Dec 18, 2023InitiatedNNoble Capital MarketsOutperform$4+189.9%

Peers

Mkt cap
TickerCompanyMkt cap
MISTMilestone Pharmaceuticals Inc84.03M
TENXTenax Therapeutics Inc77.64M
MLYSMineralys Therapeutics Inc1.42B
XRTXXORTX Therapeutics Inc1.53M
DMACDiaMedica Therapeutics Inc527.39M
LSTALisata Therapeutics Inc13.29M
PCSAProcessa Pharmaceuticals Inc5.06M
BRTXBioRestorative Therapies Inc2.10M
MTVAMetaVia Inc9.29M
UNCYUnicycive Therapeutics Inc104.32M

Insider trading

latest 14 of 26
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Pham Quang XChairman and CEOJun 29 '26Sale3.037,40022,42298,589Jul 01 09:52 PM
Pham Quang XChairman, CEO and Interim CFOJun 26 '26Sale3.059,02927,538105,989Jun 26 08:44 PM
Pham Quang XChairman, CEO and Interim CFOJun 25 '26Sale3.002,1276,381115,018Jun 26 08:44 PM
Pham Quang XChairman, CEO and Interim CFOJun 22 '26Sale3.559,16732,543119,422Jun 24 05:15 PM
Pham Quang XChairman, CEO and Interim CFOJun 23 '26Sale3.202,2777,286117,145Jun 24 05:15 PM
Pham Quang XChairman, CEO and Interim CFOJun 16 '26Sale3.183,61311,489129,102Jun 18 06:36 PM
Pham Quang XChairman, CEO and Interim CFOJun 17 '26Sale3.165131,621128,589Jun 18 06:36 PM
Pham Quang XChairman, CEO and Interim CFOJun 12 '26Sale3.9412,99651,204136,381Jun 15 08:58 PM
Pham Quang XChairman, CEO and Interim CFOJun 15 '26Sale3.583,66613,124132,715Jun 15 08:58 PM
Pham Quang XChairman, CEO and Interim CFOJun 11 '26Sale4.121,4626,023149,377Jun 15 08:58 PM
Quang X. PhamOfficerJun 15 '26Proposed Sale3.7140,000148,400Jun 15 08:16 PM
Pham Quang XChairman, CEO and Interim CFOJun 09 '26Sale4.0612,99252,748154,339Jun 10 08:26 PM
Pham Quang XChairman, CEO and Interim CFOJun 08 '26Sale4.385,89325,811167,331Jun 10 08:26 PM
Pham Quang XChairman, CEO and Interim CFOJun 10 '26Sale4.213,50014,735150,839Jun 10 08:26 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 200
  • Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics (GlobeNewswire)
  • Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference (GlobeNewswire)
  • Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference (GlobeNewswire)
  • Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia (GlobeNewswire) +13.64%
  • Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process (GlobeNewswire)
  • Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation (GlobeNewswire)
  • Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation (GlobeNewswire)
  • Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress (GlobeNewswire) -16.26%
  • Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +10.60% -5.09%
  • Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress (GlobeNewswire)
  • Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease (GlobeNewswire) +12.90%
  • Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 (GlobeNewswire) -10.00%
  • Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event (GlobeNewswire)
  • Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-1.140-1.420-1.1400.000.003
2026Q12026-05-07-1.040-1.510-1.0370.000.003
2025Q42026-03-31-1.370-1.165-1.4110.000.002
2025Q32025-11-10-1.310-1.550-1.3140.000.001
2025Q22025-08-11-1.870-1.775-1.8700.000.002
2025Q12025-05-08-2.090-2.150-2.0850.000.001
2024Q42025-03-13-2.030-1.720-2.7460.000.002
2024Q32024-11-07-2.180-1.927-2.1810.000.003
2024Q22024-08-07-2.250-1.275-2.2420.000.002
2024Q12024-05-10-1.500-1.125-1.5590.000.002
2023Q42024-03-11-1.050-1.200-1.3180.000.001
2023Q32023-11-29-1.050-1.050-1.1940.000.001
2026Q3---0.913--0.003
2026Q4---0.860--0.003
2027Q1---0.880--0.001
2027Q2---0.900--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-9.300-8.550-9.6260.000.00
2024FY-8.730-7.600-8.7340.000.00
2025FY-6.640-6.360-6.6400.000.00
2026FY--3.863--0.00
2027FY--3.007--0.00
2028FY--1.850--0.00
2029FY-8.550---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-143000.000.000.00
2026Q3S2026-07-203000.000.000.00
2026Q3S2026-07-152000.000.000.00
2026Q3S2026-05-073000.000.000.00
2026Q3S2026-04-083000.000.000.00
2026Q3S2026-04-062000.000.000.00
2026Q3S2026-03-311000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00

Estimate history

EPS, annual-8.657-9.626-8.734-6.639-4.9027
Period2022202320242025TTM
EPS, quarterly-2.242-2.181-2.746-2.085-1.87-1.314-1.411-1.037-1.141
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.7760.8681.7822.3383.099
Period2022202320242025MRQ
Shares, quarterly1.0671.2351.7821.912.0072.062.3382.5073.099
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.010.000.000.00
Gross Profit-0.00-0.01-0.00-0.00-0.00
Selling, General and Administrative Excl. Other11.6513.4510.967.632.70
Research and Development2.834.104.214.080.39
Other Operating Expense0.000.000.000.000.00
Operating Income-11.65-13.46-10.96-7.63-2.70
Interest Expense0.000.000.000.020.11
Unusual Expense0.000.000.000.963.91
Net Income Before Taxes-11.54-13.24-10.65-8.36-6.71
Income Taxes0.000.000.000.000.00
Consolidated Net Income-11.54-13.24-10.65-8.36-6.71
Net Income From Continuing Operations-11.54-13.24-10.65-8.36-6.71
Net Income-11.54-13.24-10.65-8.36-6.71
EPS (Recurring)-3.96-6.64-8.73-8.85-5.13
EPS (Basic, Before Extraordinaries)-4.90-6.64-8.73-9.63-8.66
EPS (Diluted)-4.90-6.64-8.73-9.63-8.66
EBITDA-11.65-13.45-10.96-7.63-2.70
Non-Operating Income (Expense)0.110.220.310.250.00
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense1.721.941.420.710.93
Shares Outstanding3.102.341.780.870.78
Market Capitalization5.145.1424.049.649.64

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.010.000.00
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.01-0.00-0.00
Selling, General and Administrative Excl. Other3.342.513.062.733.733.924.282.46
Research and Development0.710.770.670.691.081.671.540.78
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.34-2.51-3.07-2.73-3.73-3.93-4.28-2.46
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00-0.00
Net Income Before Taxes-3.32-2.50-3.04-2.69-3.67-3.85-4.19-2.41
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.32-2.50-3.04-2.69-3.67-3.85-4.19-2.41
Net Income From Continuing Operations-3.32-2.50-3.04-2.69-3.67-3.85-4.19-2.41
Net Income-3.32-2.50-3.04-2.69-3.67-3.85-4.19-2.41
EPS (Recurring)-1.14-1.04-1.41-1.31-1.87-2.09-2.75-2.18
EPS (Basic, Before Extraordinaries)-1.14-1.04-1.41-1.31-1.87-2.09-2.75-2.18
EPS (Diluted)-1.14-1.04-1.41-1.31-1.87-2.09-2.75-2.18
EBITDA-3.34-2.51-3.06-2.73-3.73-3.92-4.28-2.46
Non-Operating Income (Expense)0.020.020.030.050.070.080.090.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.670.250.330.470.590.550.760.30
Shares Outstanding3.102.512.342.062.011.911.781.23
Market Capitalization5.1411.9715.8528.3123.7033.1424.0414.57

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments4.0110.028.400.03
Short Term Receivables0.010.040.000.00
Inventories0.000.000.000.00
Other Current Assets0.200.040.090.02
Total Current Assets4.2110.108.490.06
Net Property, Plant & Equipment0.010.010.020.04
Total Investments and Advances0.000.000.000.00
Other Assets0.110.020.000.68
Total Assets4.3310.128.520.78
Short Term Debt Incl. Current Port. of LT Debt0.000.000.020.07
Accounts Payable0.651.500.170.40
Other Current Liabilities0.941.180.640.86
Total Current Liabilities1.592.680.831.33
Long Term Debt0.000.000.000.57
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.000.004.42
Total Liabilities1.592.680.836.33
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity2.747.447.69-5.55
Total Shareholders Equity2.747.447.69-5.55
Accumulated Minority Interest0.000.000.000.00
Total Equity2.747.447.69-5.55
Total Liabilities & Stockholders Equity4.3310.128.520.78
Book Value Per Share1.174.178.86-7.16
Tangible Book Value Per Share1.174.178.86-7.16
Full-Time Employees5443
Price to Book Ratio1.095.241.101.10
Return on Assets-183.21-114.27-179.77-
Return on Equity-260.11-140.78-780.59-
Return on Invested Capital-483.34-143.17-108.64-
Quick Ratio2.653.7610.270.04
Current Ratio2.653.7610.270.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-11.54-13.24-10.65-8.36-6.71
Depreciation0.000.010.000.000.00
Other Funds (Non Cash)1.721.941.424.684.90
Funds from Operations-9.82-11.29-9.23-3.67-1.81
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-0.34-1.311.870.140.61
Cash from Operating Activities-10.16-12.60-7.36-3.53-1.20
Capital Expenditures-0.00-0.01-0.01-0.000.00
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00-0.00
Purchase of Investments0.000.000.000.00-0.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-0.00-0.01-0.01-0.00-0.00
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock6.986.608.9812.151.24
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock6.986.608.9812.151.24
Proceedsfrom Stock Options7.016.608.9811.901.24
Issuance or Reduction of Debt, Net0.000.000.00-0.250.00
Change in Long Term Debt0.000.000.00-0.250.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.250.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities6.986.608.9811.901.24
Net Change in Cash-3.18-6.011.628.370.03
Free Cash Flow-10.16-12.61-7.36-3.53-1.20
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.392.314.013.865.577.34
Short Term Receivables2.690.010.010.010.020.02
Inventories0.000.000.000.000.000.00
Other Current Assets0.410.430.200.120.360.58
Total Current Assets5.492.744.213.995.957.94
Net Property, Plant & Equipment0.000.000.010.010.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.100.120.110.090.030.01
Total Assets5.592.864.334.095.987.95
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.870.820.650.610.901.28
Other Current Liabilities0.630.240.940.740.780.56
Total Current Liabilities1.501.061.591.351.681.84
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.501.061.591.351.681.84
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.091.802.742.734.306.11
Total Shareholders Equity4.091.802.742.734.306.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.091.802.742.734.306.11
Total Liabilities & Stockholders Equity5.592.864.334.095.987.95
Book Value Per Share1.320.721.171.332.143.20
Tangible Book Value Per Share1.320.721.171.332.143.20
Full-Time Employees--5---
Price to Book Ratio1.094.375.116.463.764.22
Return on Assets-199.59-219.85-183.21-328.18-246.73-171.09
Return on Equity-275.16-300.59-260.11-468.03-340.31-208.59
Return on Invested Capital-81.20-138.92-110.96-98.20-85.31-62.90
Quick Ratio3.672.572.652.953.544.31
Current Ratio3.672.572.652.953.544.31

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.32-2.50-3.04-2.69-3.67-3.85
Depreciation0.000.000.000.000.000.01
Other Funds (Non Cash)0.670.250.330.470.590.55
Funds from Operations-2.65-2.24-2.71-2.21-3.07-3.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.42-0.760.14-0.150.05-1.36
Cash from Operating Activities-2.23-3.00-2.57-2.36-3.03-4.65
Capital Expenditures0.000.000.00-0.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.000.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.311.302.720.651.261.97
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.311.302.720.651.261.97
Proceedsfrom Stock Options2.311.302.770.631.231.97
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.311.302.720.651.261.97
Net Change in Cash0.08-1.700.15-1.71-1.77-2.68
Free Cash Flow-2.23-3.00-2.57-2.36-3.03-4.65

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.16%0.2M3.2M462.92K
2026-10-158.74%0.3M3.2M461.53K
2026-09-303.29%0.1M3.2M432.71K
2026-09-153.69%0.1M3.2M432.82K
2026-08-312.74%0.1M3.2M404.60K
2026-08-142.05%0.1M3.2M69.75K
2026-07-311.95%0.1M3.1M75.59K
2026-07-152.11%0.1M2.6M78.55K
2026-06-303.36%0.1M2.4M63.10K
2026-06-153.00%0.1M2.4M60.79K
2026-05-293.00%0.1M2.3M54.16K
2026-05-153.12%0.1M2.3M57.47K
2026-04-302.44%0.1M2.2M50.92K
2026-04-152.23%0.0M2.0M46.73K
2026-03-311.51%0.0M2.0M52.26K
2026-03-134.11%0.1M1.8M59.35K
2026-02-276.06%0.1M1.8M63.18K
2026-02-133.10%0.1M1.8M54.68K
2026-01-303.92%0.1M1.8M52.26K
2026-01-153.21%0.1M1.8M48.51K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-078-KCurrent report2026-10-07SEC
2026-09-298-KCurrent report2026-09-24SEC
2026-09-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-318-KCurrent report2026-08-31SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-07SCHEDULE 13GSEC
2026-08-03DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-03ARSAnnual report to security holders. 2025-12-31SEC
2026-08-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-24SEC
2026-07-23PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-23SEC
2026-07-218-KCurrent report2026-07-21SEC
2026-07-20EFFECTEffectiveness filing by commission orderSEC
2026-07-20424B3SEC
2026-07-178-KCurrent report2026-07-14SEC
2026-07-15DNotice of sales of securities on Form D (Regulation D)SEC
2026-07-13S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-108-KCurrent report2026-07-07SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-018-KCurrent report2026-06-30SEC
2026-06-298-KCurrent report2026-06-25SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0600310.69K17
2026-050077.60K5
2026-040000
2026-030000
2026-020000
2026-010000
2025-120069.23K1
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.75%
HRT FINANCIAL LP1.01%
COURIER CAPITAL LLC0.56%
Vectors Research Management, LLC0.56%
GEODE CAPITAL MANAGEMENT, LLC0.53%
Squarepoint Ops LLC0.35%
VANGUARD FIDUCIARY TRUST CO0.29%
Nuveen, LLC0.20%
UBS Group AG0.16%
BARCLAYS PLC0.11%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.16%
VANGUARD EXTENDED MARKET INDEX FUND0.59%
Fidelity Extended Market Index Fund0.34%
Fidelity Series Total Market Index Fund0.07%
Fidelity Nasdaq Composite Index Fund0.06%
Fidelity Total Market Index Fund0.03%
Dimensional US Sustainability Core 1 ETF0.03%
U.S. Social Core Equity 2 Portfolio0.02%

OakChart. CVKD. Cached 15 minutes.